Drug Trial Radar · NCT02551055
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Sep 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
32
Actual
Start
Oct 15, 2015
Primary completion
Feb 17, 2017
Study completion Feb 17, 2017
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational alisertib in adult participants with advanced and metastatic gastric or gastroesophageal adenocarcinoma. The study consists of a dose escalation phase (Part 1) and a dose expansion phase (Part 2).
Conditions
- Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
Interventions
MLN1117Drug
MLN1117 Tablets
TAK-659Drug
TAK-659 Tablets
AlisertibDrug
Alisertib Tablets
PaclitaxelDrug
Paclitaxel intravenous infusion
DocetaxelDrug
Docetaxel intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT) in Part 1Time frame: Up to Cycle 1 (28 days for MLN1117+TAK-659, MLN1117+Alisertib, MLN1117+Paclitaxel or 21 days for MLN1117+Docetaxel)
- Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) in Part 1Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
- Number of Participants With at Least 1 ≥ Grade 3 TEAE in Part 1Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
- Number of Participants With at Least 1 Treatment-Emergent Serious Adverse Event (SAE) in Part 1Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
- Number of Participants With at Least 1 Dose Modification Due to AE in Part 1Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
- Overall Response Rate in Part 2Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Lake Success, New York
Site not named
New York, New York
Site not named
Philadelphia, Pennsylvania
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.